Lena M. Berger

410 total citations
19 papers, 234 citations indexed

About

Lena M. Berger is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Lena M. Berger has authored 19 papers receiving a total of 234 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Oncology and 4 papers in Cell Biology. Recurrent topics in Lena M. Berger's work include Microtubule and mitosis dynamics (4 papers), Protein Degradation and Inhibitors (4 papers) and Ubiquitin and proteasome pathways (4 papers). Lena M. Berger is often cited by papers focused on Microtubule and mitosis dynamics (4 papers), Protein Degradation and Inhibitors (4 papers) and Ubiquitin and proteasome pathways (4 papers). Lena M. Berger collaborates with scholars based in Germany, United States and Finland. Lena M. Berger's co-authors include Stefan Knapp, Benedict‐Tilman Berger, Thomas Hanke, Andreas Krämer, Susanne Müller, Matthew B. Robers, James D. Vasta, Roberta Tesch, Andreas C. Joerger and Volker Dötsch and has published in prestigious journals such as The FASEB Journal, International Journal of Molecular Sciences and Journal of Medicinal Chemistry.

In The Last Decade

Lena M. Berger

18 papers receiving 228 citations

Peers

Countries citing papers authored by Lena M. Berger

Since Specialization

Citations

This map shows the geographic impact of Lena M. Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lena M. Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lena M. Berger more than expected).

Fields of papers citing papers by Lena M. Berger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lena M. Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lena M. Berger. The network helps show where Lena M. Berger may publish in the future.

Co-authorship network of co-authors of Lena M. Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Lena M. Berger. A scholar is included among the top collaborators of Lena M. Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lena M. Berger. Lena M. Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Inhibition of DYRK1B BY C81 impedes inflammatory processes in leukocytes by reducing STAT3 activity 2025 ·Cellular and Molecular Life Sciences ·(unknown), (unknown), (unknown), Anne Wolf, (unknown), Dominik C. Fuhrmann, Dominique Thomas, Robert Gurke, Martin P. Schwalm, Lena M. Berger, (unknown), (unknown), Rolf Marschalek, Gerd Geißlinger, Stefan Knapp, Thomas Langmann, Franz Bracher, Andreas Weigert, Robert Fürst	1
2	Back-Pocket Optimization of 2-Aminopyrimidine-Based Macrocycles Leads to Potent EPHA2/GAK Kinase Inhibitors 2024 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Andreas Krämer, (unknown), Tran Do Hoang Nhu, Andreas C. Joerger, Christian Schreiber, Lena M. Berger, Benedict‐Tilman Berger, (unknown), (unknown), (unknown), Krishna Saxena, Susanne Müller, Shirit Einav, Stefan Knapp, Thomas Hanke	8
3	Development of Selective Pyrido[2,3- d ]pyrimidin-7(8 H )-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors 2024 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Roberta Tesch, Lena M. Berger, (unknown), (unknown), Andreas Krämer, (unknown), Benedict‐Tilman Berger, (unknown), L M Wahl, Antti Poso, Astrid Kaiser, Thomas Hanke, Thales Kronenberger, Andreas C. Joerger, Susanne Müller, Stefan Knapp	3
4	Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization 2024 ·ACS Chemical Biology ·(unknown), (unknown), Joel R. Schneider, Xin Zhang, Lena M. Berger, Benedict‐Tilman Berger, Martin P. Schwalm, N. Klopp, Jens T. Siveke, Stefan Knapp, Andreas C. Joerger	6
5	Deep Annotation of Donated Chemical Probes (DCP) in Organotypic Human Liver Cultures and Patient-Derived Organoids from Tumor and Normal Colorectum 2023 ·ACS Chemical Biology ·Claudia Tredup, (unknown), Natalie Schneider, (unknown), (unknown), Sonia Youhanna, Volker M. Lauschke, Benedict‐Tilman Berger, Andreas Krämer, Lena M. Berger, (unknown), Stefan Knapp, Henner F. Farin, Susanne Müller	0
6	Shifting the selectivity of pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily 2023 ·European Journal of Medicinal Chemistry ·(unknown), Roberta Tesch, Lena M. Berger, (unknown), Monika Raab, (unknown), (unknown), (unknown), Andreas C. Joerger, Antti Poso, Andreas Krämer, (unknown), (unknown), Thales Kronenberger, Thomas Hanke, Klaus Strebhardt, Mourad Sanhaji, Stefan Knapp	6
7	Design and Synthesis of Pyrazole-Based Macrocyclic Kinase Inhibitors Targeting BMPR2 2023 ·ACS Medicinal Chemistry Letters ·(unknown), (unknown), Benedict‐Tilman Berger, Lena M. Berger, (unknown), Andreas Krämer, Stefan Knapp, Thomas Hanke	9
8	Synthesis of Pyrazole-Based Macrocycles Leads to a Highly Selective Inhibitor for MST3 2023 ·Journal of Medicinal Chemistry ·(unknown), Lena M. Berger, (unknown), Andreas C. Joerger, (unknown), Andreas Krämer, (unknown), Benedict‐Tilman Berger, (unknown), Astrid Kaiser, Manfred Schubert‐Zsilavecz, Susanne Müller, Stefan Knapp, Thomas Hanke	8
9	Discovery of 3-Amino-1H-pyrazole-Based Kinase Inhibitors to Illuminate the Understudied PCTAIRE Family 2022 ·International Journal of Molecular Sciences ·(unknown), Lena M. Berger, (unknown), Andreas Krämer, (unknown), (unknown), (unknown), Astrid Kaiser, Manfred Schubert‐Zsilavecz, Susanne Müller, Stefan Knapp, Thomas Hanke	5
10	A Toolbox for the Generation of Chemical Probes for Baculovirus IAP Repeat Containing Proteins 2022 ·Frontiers in Cell and Developmental Biology ·Martin P. Schwalm, Lena M. Berger, (unknown), James D. Vasta, Cesear Corona, (unknown), Benedict‐Tilman Berger, (unknown), (unknown), (unknown), (unknown), Vladimir V. Rogov, Sebastian Mathea, Krishna Saxena, Matthew B. Robers, Susanne Müller, Stefan Knapp	10
11	Illuminating the Dark: Highly Selective Inhibition of Serine/Threonine Kinase 17A with Pyrazolo[1,5- a ]pyrimidine-Based Macrocycles 2022 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), (unknown), (unknown), Deep Chatterjee, Sebastian Mathea, Lena M. Berger, Benedict‐Tilman Berger, Andreas Krämer, Michael Weller, Tobias Weiß, Susanne Müller, Stefan Knapp, Thomas Hanke	17
12	Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells 2022 ·ACS Pharmacology & Translational Science ·(unknown), Michael Förster, (unknown), (unknown), (unknown), (unknown), (unknown), Lena M. Berger, Stefan Knapp, Dieter Schollmeyer, (unknown), Michael Burnet, Stefan Laufer	4
13	Inhibitors of the Hippo Pathway Kinases STK3/MST2 and STK4/MST1 Have Utility for the Treatment of Acute Myeloid Leukemia 2021 ·Journal of Medicinal Chemistry ·(unknown), A. Chaikuad, (unknown), Allison S. Limpert, Lester J. Lambert, Douglas J. Sheffler, Lena M. Berger, (unknown), (unknown), Li Wang, Yi Peng, Jing Dong, Maria Celeridad, (unknown), Stefan Knapp, Nicholas D. P. Cosford	23
14	Single tracer-based protocol for broad-spectrum kinase profiling in live cells with NanoBRET 2021 ·STAR Protocols ·Matthew B. Robers, Jennifer Wilkinson, James D. Vasta, Lena M. Berger, Benedict‐Tilman Berger, Stefan Knapp	14
15	Design of a “Two-in-One” Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites 2021 ·Journal of Medicinal Chemistry ·(unknown), David E. Heppner, Ciric To, Marcel Günther, Bo Hee Shin, (unknown), Anna M. Schmoker, Tyler S. Beyett, Lena M. Berger, Benedict‐Tilman Berger, (unknown), James D. Vasta, Cesear Corona, Matthew B. Robers, Stefan Knapp, Pasi A. Jänne, Michael J. Eck, Stefan Laufer	26
16	C81‐evoked inhibition of the TNFR1‐NFκB pathway during inflammatory processes for stabilization of the impaired vascular endothelial barrier for leukocytes 2021 ·The FASEB Journal ·(unknown), (unknown), (unknown), (unknown), Lena M. Berger, Christoph A. Reichel, (unknown), Tobias Schmid, Stefan Knapp, Susanne Müller, Franz Bracher, Robert Fürst, (unknown)	4
17	Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors 2021 ·Journal of Medicinal Chemistry ·Roberta Tesch, (unknown), Monika Raab, Lena M. Berger, Thales Kronenberger, Andreas C. Joerger, Benedict‐Tilman Berger, (unknown), Thomas Hanke, Antti Poso, Klaus Strebhardt, Mourad Sanhaji, Stefan Knapp	26
18	Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders 2021 ·Journal of Medicinal Chemistry ·(unknown), Bikash Adhikari, Andreas Krämer, (unknown), (unknown), Lena M. Berger, (unknown), Magdalena M. Szewczyk, Dalia Baršytė-Lovejoy, C.H. Arrowsmith, Jakob Gebel, Frank Löhr, Volker Dötsch, Martin Eilers, Stephanie Heinzlmeir, Bernhard Küster, Christoph Sotriffer, Elmar Wolf, Stefan Knapp	48
19	A Highly Selective Chemical Probe for Activin Receptor-like Kinases ALK4 and ALK5 2020 ·ACS Chemical Biology ·Thomas Hanke, Jong Fu Wong, Benedict‐Tilman Berger, (unknown), Lena M. Berger, Roberta Tesch, Claudia Tredup, Alex N. Bullock, Susanne Müller, Stefan Knapp	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact